Eris Lifesciences quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	892	792	+12.6%
EBITDA	309	288	+7.3%
EBITDA margin	34.7%	36.4%	−1.7 pts
Profit before tax	157	172	−9.0%
Net profit	187	134	+39.2%
EPS	₹13.26	₹8.82	+50.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	892	873	757	807	792	773	705	727	739	720	551	486	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	3.2	2.4	2.2	0.0	2.8	2.7	8.0	4.2	6.8	1.6	15.1	4.2
	896	876	759	807	795	776	713	732	746	721	566	490
	108	94.3	68.1	106	82.6	70.1	68.3	69.4	72.2	66.5	51.2	38.9
	168	131	123	117	146	104	96.0	133	118	126	58.5	50.0
	−49.9	13.9	−5.8	0.2	−26.3	10.3	6.0	−25.8	−4.2	−11.5	8.5	−0.1
	149	153	137	138	137	144	121	125	126	133	102	98.7
	46.4	46.7	45.6	48.8	49.6	48.7	54.3	57.2	59.5	60.4	33.0	18.1
	73.4	72.1	69.6	70.3	69.1	70.5	77.3	81.2	80.5	75.9	53.9	45.7
	208	184	161	164	164	167	161	175	165	157	182	123
	703	696	598	645	623	615	584	616	617	606	489	375
	309	296	274	282	288	277	252	250	262	250	148	176
	236	224	204	211	219	206	175	169	182	174	94.5	130
Profit
	193	180	161	162	172	160	129	116	129	115	76.6	116
	−35.9	0.0	0.0	−17.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	157	180	161	145	172	160	129	116	129	115	76.6	116
	−64.8	31.1	12.5	17.4	71.2	56.3	31.4	24.9	30.2	25.3	15.7	19.4
	33.6	5.1	−132	19.1	−33.0	−20.3	−4.9	4.4	2.5	0.6	−18.7	−5.0
	−31.2	36.2	−120	36.5	38.2	36.0	26.5	29.2	32.8	25.9	−3.0	14.4
	−0.9	−0.4	−1.2	0.1	0.3	0.9	0.1	0.0	0.0	0.0	0.0	0.0
	187	143	279	109	134	125	102	86.9	96.4	89.4	79.6	101
	188	144	280	109	134	124	102	86.9	96.4	89.4	79.6	101
	−1.2	0.1	0.4	−0.7	−0.6	−0.6	−2.0	−0.4	−0.2	−0.8	−0.4	−0.3
	186	143	280	108	134	125	100	86.5	96.2	88.6	79.2	101
	184	142	282	99.7	120	118	93.8	83.6	91.6	83.2	71.0	103
	3.3	0.9	−2.5	9.1	14.3	7.1	8.5	3.3	4.8	6.2	8.7	−1.3
Per share
	₹13.26	₹10.28	₹20.60	₹7.32	₹8.82	₹8.66	₹6.90	₹6.15	₹6.73	₹6.11	₹5.22	₹7.55
	₹13.25	₹10.26	₹20.57	₹7.31	₹8.81	₹8.64	₹6.89	₹6.14	₹6.72	₹6.10	₹5.21	₹7.54
Other comprehensive income — detail
	−1.2	0.1	0.4	−0.7	−0.6	−0.6	−2.0	—	—	—	—	—
	0.2	0.2	2.6	−0.8	—	−0.8	−1.6	−0.6	−0.3	−1.2	−0.8	−0.4
	0.0	0.0	0.6	−0.3	0.8	−0.3	0.3	—	—	—	—	—
	—	—	—	—	—	—	—	−0.2	−0.1	−0.4	−0.3	−0.1
	−1.7	−0.0	−2.2	−0.2	—	—	—	—	—	—	—	—
	−0.4	0.0	−0.6	−0.0	−0.3	—	—	—	—	—	—	—
	183	143	282	99.0	120	117	92.0	83.2	91.4	82.4	70.6	102
	3.3	0.9	−2.4	9.1	14.3	7.4	8.4	3.3	4.8	6.2	8.7	−1.3
Per share — as-filed variants
	₹13.26	₹10.28	₹20.60	₹7.32	₹8.82	₹8.66	₹6.90	₹6.15	₹6.73	₹6.11	₹5.22	₹7.55
	₹13.25	₹10.26	₹20.57	₹7.31	₹8.81	₹8.64	₹6.89	₹6.14	₹6.72	₹6.10	₹5.21	₹7.54
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	667	634	571	584	590	588	535	551	553	539	433	397
	74.7%	72.6%	75.5%	72.3%	74.5%	76.1%	75.9%	75.7%	74.8%	74.9%	78.5%	81.7%
Adjusted (ex-exceptional items) — derived
	193	180	161	162	172	160	129	116	129	115	76.6	116
	−35.9	0.0	0.0	−17.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	223	143	279	122	134	125	102	86.9	96.4	89.4	79.6	101
	₹15.80	₹10.28	₹20.60	₹8.19	₹8.82	₹8.66	₹6.90	₹6.15	₹6.73	₹6.11	₹5.22	₹7.55

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMANKIND AJANTPHARM TORNTPHARM EMCURE GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹16,116 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	486.3	550.9	719.7	739.0	727.5	705.3	773.0	792.4	807.5	756.6	873.3	892.4
Other Income	4.2	15.1	1.6	6.8	4.2	8.0	2.7	2.8	0.0	2.2	2.4	3.2
Total Income	490.5	566.1	721.4	745.7	731.7	713.3	775.7	795.2	807.5	758.8	875.6	895.6
Expenses
+ Cost of Materials Consumed	38.9	51.2	66.5	72.2	69.4	68.3	70.1	82.6	105.9	68.1	94.3	107.9
+ Purchases of Stock-in-Trade	50.0	58.5	125.6	118.4	133.2	96.0	104.3	146.1	117.2	123.0	131.1	167.7
+ Changes in Inventories	-0.1	8.5	-11.5	-4.2	-25.8	6.0	10.3	-26.3	0.2	-5.8	13.9	-49.9
+ Employee Benefit Expense	98.7	102.5	132.6	125.6	125.4	121.5	144.4	137.5	138.1	136.9	153.4	149.2
+ Finance Costs	18.1	33.0	60.4	59.5	57.2	54.3	48.7	49.6	48.8	45.6	46.7	46.4
+ Depreciation & Amortisation	45.7	53.9	75.9	80.5	81.2	77.3	70.5	69.1	70.3	69.6	72.1	73.4
+ Other Expenses	123.2	181.8	156.5	164.8	174.9	161.2	167.2	164.3	164.5	160.9	184.4	208.1
Total Expenses	374.6	489.4	606.0	616.6	615.5	584.4	615.5	622.8	645.0	598.2	695.8	702.9
EBITDA	175.5	148.4	250.0	262.3	250.3	252.4	276.7	288.2	281.6	273.6	296.2	309.4
EBIT	129.8	94.5	174.1	181.8	169.1	175.1	206.2	219.1	211.3	204.0	224.2	235.9
Profit
PBT before Exceptional Items	115.9	76.6	115.3	129.1	116.2	128.8	160.2	172.4	162.5	160.6	179.9	192.7
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-17.2	0.0	0.0	-35.9
Pretax Income	115.9	76.6	115.3	129.1	116.2	128.8	160.2	172.4	145.2	160.6	179.9	156.8
+ Current Tax	19.4	15.7	25.3	30.2	24.9	31.4	56.3	71.2	17.4	12.5	31.1	-64.8
+ Deferred Tax	-5.0	-18.7	0.6	2.5	4.4	-4.9	-20.3	-33.0	19.1	-132.2	5.1	33.6
Tax Expense	14.4	-3.0	25.9	32.8	29.2	26.5	36.0	38.2	36.5	-119.7	36.2	-31.2
+ Share of Associates & JVs	0.0	0.0	0.0	0.0	0.0	0.1	0.9	0.3	0.1	-1.2	-0.4	-0.9
Net Income	101.5	79.6	89.4	96.4	86.9	102.4	125.1	134.5	108.8	279.1	143.3	187.1
+ Net Income — Continuing Ops	101.5	79.6	89.4	96.4	86.9	102.3	124.2	134.2	108.7	280.3	143.7	188.0
+ Other Comprehensive Income	-0.3	-0.4	-0.8	-0.2	-0.4	-2.0	-0.6	-0.6	-0.7	0.4	0.1	-1.2
Total Comprehensive Income	101.1	79.2	88.6	96.2	86.5	100.4	124.5	133.9	108.1	279.5	143.4	186.0
Net Income to Common	102.7	71.0	83.2	91.6	83.6	93.8	118.0	120.2	99.7	281.6	142.5	183.8
Minority Interest	-1.3	8.7	6.2	4.8	3.3	8.5	7.1	14.3	9.1	-2.5	0.9	3.3
Per Share
Basic EPS	7.55	5.22	6.11	6.73	6.15	6.90	8.66	8.82	7.32	20.60	10.28	13.26
Diluted EPS	7.54	5.21	6.10	6.72	6.14	6.89	8.64	8.81	7.31	20.57	10.26	13.25
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-2.0	-0.6	-0.6	-0.7	0.4	0.1	-1.2
+ Items NOT to be Reclassified to P&L	-0.4	-0.8	-1.2	-0.3	-0.6	-1.6	-0.8	—	-0.8	2.6	0.2	0.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.3	-0.3	0.8	-0.3	0.6	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.3	-0.4	-0.1	-0.2	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	—	—	-0.2	-2.2	-0.0	-1.7
+ Tax on Items to be Reclassified	—	—	—	—	—	—	—	-0.3	-0.0	-0.6	0.0	-0.4
Comprehensive Income — Owners of Parent	102.4	70.6	82.4	91.4	83.2	92.0	117.2	119.6	99.0	282.0	142.5	182.7
Comprehensive Income — Non-controlling Interests	-1.3	8.7	6.2	4.8	3.3	8.4	7.4	14.3	9.1	-2.4	0.9	3.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	7.55	5.22	6.11	6.73	6.15	6.90	8.66	8.82	7.32	20.60	10.28	13.26
Diluted EPS — Continuing Operations	7.54	5.21	6.10	6.72	6.14	6.89	8.64	8.81	7.31	20.57	10.26	13.25
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	397.4	432.7	539.1	552.7	550.6	535.1	588.4	590.0	584.2	571.3	634.0	666.6
Gross Margin %	81.73	78.55	74.91	74.79	75.69	75.86	76.11	74.46	72.35	75.51	72.60	74.70
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	115.9	76.6	115.3	129.1	116.2	128.8	160.2	172.4	162.5	160.6	179.9	192.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-17.2	0.0	0.0	-35.9
Net Income Adj (tax-effected)	101.5	79.6	89.4	96.4	86.9	102.4	125.1	134.5	121.7	279.1	143.3	223.0
EPS Adj	7.55	5.22	6.11	6.73	6.15	6.90	8.66	8.82	8.19	20.60	10.28	15.80
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Filed Debt Equity	—	—	—	1.00	1.00	0.76	0.74	0.68	0.67	0.61	0.64	0.59
Filed Dscr	—	—	—	2.00	2.00	2.36	2.60	2.65	2.48	3.95	2.75	3.12
Filed Iscr	—	—	—	3.00	3.00	3.37	4.29	4.48	4.33	4.52	4.86	5.15
Paid Up Equity Capital	13.6	13.6	13.6	13.6	13.6	13.6	13.6	13.6	13.6	13.9	13.9	13.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Eris Lifesciences Q2 FY27 results (July–September 2026)

Filed with NSE on Monday, 26 October 2026 at 1:49 pm IST

Eris Lifesciences (NSE: ERIS) reported its Q2 FY27 results (July–September 2026) on Monday, 26 October 2026 at 1:49 pm IST. Consolidated net profit attributable to shareholders was ₹184 crore, up 52.9% from ₹120 crore in Q2 FY26 and up 29.0% from ₹142 crore in Q1 FY27. Revenue from operations was ₹892 crore, up 12.6% year on year and up 2.2% from the previous quarter.

Q2 FY26 results (a year earlier): 12 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹184 Cr+52.9% vs Q2 FY26+29.0% vs Q1 FY27Total incl. minority interest ₹187 Cr
Revenue from operations: ₹892 Cr+12.6% vs Q2 FY26+2.2% vs Q1 FY27
Operating margin (EBIT): 26.4%−1.2 pts vs Q2 FY26+0.8 pts vs Q1 FY27EBIT ₹236 Cr
EBITDA: ₹309 Cr+7.3% vs Q2 FY26+4.4% vs Q1 FY27margin 34.7%
Earnings per share (basic): ₹13.26+50.3% vs Q2 FY26+29.0% vs Q1 FY27
Net profit margin: 20.6%+5.4 pts vs Q2 FY26+4.3 pts vs Q1 FY27

Questions

What was Eris Lifesciences' net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹184 crore, up 52.9% from ₹120 crore in Q2 FY26 and up 29.0% from ₹142 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹187 crore.

How were Eris Lifesciences' Q2 FY27 results?

Both grew from a year earlier: net profit was up 52.9% at ₹184 crore and revenue was up 12.6% at ₹892 crore. The operating margin was 26.4%, down 1.2 percentage points from 27.7% a year earlier. Against Q1 FY27, net profit was up 29.0% and revenue up 2.2%.

What was Eris Lifesciences' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹236 crore, a margin of 26.4%, against 25.7% in Q1 FY27 and 27.7% in Q2 FY26. EBITDA was ₹309 crore, 34.7% of revenue.

What was Eris Lifesciences' revenue in Q2 FY27?

Revenue from operations was ₹892 crore, up 12.6% year on year and up 2.2% from the previous quarter.

What was Eris Lifesciences' EPS in Q2 FY27?

Basic earnings per share were ₹13.26, against ₹8.82 in Q2 FY26.

What was Eris Lifesciences' revenue in FY26?

Revenue from operations was ₹3,129 crore in FY26 (April 2025–March 2026), up 8.1% from ₹2,894 crore in FY25. It was ₹2,009 crore in FY24 and ₹1,685 crore in FY23: up 85.7% over three years, 22.9% a year on average.

What was Eris Lifesciences' net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹326 crore, up 37.0% from ₹238 crore in the same months a year earlier. Revenue from operations was ₹1,766 crore, up 12.8%.

What is Eris Lifesciences' net profit margin?

Eris Lifesciences' net profit margin was 20.6% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 15.2% in Q2 FY26 (up 5.4 percentage points). For FY26 as a whole it was 19.8%.

What was Eris Lifesciences' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹620 crore in FY26 (April 2025–March 2026), up 76.1% from ₹352 crore in FY25. It was ₹392 crore in FY24 and ₹382 crore in FY23: up 62.1% over three years, 17.5% a year on average.

How has Eris Lifesciences' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹99.7 crore in Q3 FY26, ₹282 crore in Q4 FY26, ₹142 crore in Q1 FY27 and ₹184 crore in Q2 FY27. That is ₹708 crore over the four quarters, up 70.2% from ₹416 crore in the four quarters before. Revenue from operations: ₹807 crore, ₹757 crore, ₹873 crore and ₹892 crore.

When did Eris Lifesciences announce its Q2 FY27 results?

On Monday, 26 October 2026 at 1:49 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 12 November 2025.

When will Eris Lifesciences announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Eris Lifesciences figures come from?

From Eris Lifesciences' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 26 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.